Autolus Therapeutics (AUTL) said Friday that the UK Medicines and Healthcare products Regulatory Agency granted conditional marketing authorization for Aucatzyl to treat adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
The authorization is based on results from the Felix study, an open-label, multicenter, single-arm trial in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, according to the company.
The biopharmaceutical company said it submitted obecabtagene autoleucel, an autologous CD19 CAR T cell therapy with a proprietary CD19 CAR, for appraisal by the National Institute for Health and Care Excellence in Q4 2024.
Autolus is currently working with NICE and the NHS to potentially enable access for eligible patients in England.
Shares of Autolus were down 4.3% in recent trading.
Price: 1.34, Change: -0.06, Percent Change: -4.29
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.